American Society of Hematology Announces 2016 Translational Research Training in Hematology Program Participants
(WASHINGTON, May 2, 2016) – The American Society of Hematology (ASH) and the European Hematology Association (EHA) have announced the names of 20 early-career hematologists participating in the 2016 Translational Research Training in Hematology (TRTH) joint program.
TRTH offers a rigorous yearlong training and mentoring experience directed at helping junior scientists build successful careers in translational hematologic research. Under the guidance of international leaders, participants learn the fundamental principles related to translational research, including developing a hypothesis and applying the scientific method to test that hypothesis in the laboratory. TRTH participants include medical, biomedical, and pharmaceutical doctorate trainees who are actively employed in a hematology-related research environment as junior faculty or program leaders and have completed their fellowship training within the past three years.
This year’s TRTH program began with a week-long course in March 2016 designed to give participants a more profound understanding of translational research methodology. The course included didactic and interactive sessions and one-on-one faculty mentoring that focused on refining participants’ research proposals. TRTH participants will convene again at the 2016 EHA Annual Congress, June 9-12 in Copenhagen, where they will attend small group mentoring sessions. Finally, participants will present the status of their projects at the conclusion of the program at the 2016 ASH Annual Meeting, December 3-6 in San Diego.
The TRTH program is made possible by generous support from the Wallace H. Coulter Foundation, Agios Pharmaceuticals, Incyte Corporation, Takeda Oncology, and Gilead Sciences, Inc.
“Talented researchers emerge from the TRTH program with the knowledge and professional network that will position them for success as they continue to grow their careers in the important discipline of translational research,” said ASH President Charles S. Abrams, MD, of the University of Pennsylvania. “We thank our partners and donors for contributing to the success of these 20 program participants who we have no doubt will make important discoveries that will change how we treat blood disorders.”
The 2016 ASH/EHA TRTH participants are:
| Gregory Behbehani, MD, PhD | The Ohio State University, Columbus, OH |
| Melinda Biernacki, MD | University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA |
| Chun-Wei Chen, PhD | Memorial Sloan Kettering Cancer Center, New York, NY |
| Karen De Ceunynck, PhD | Beth Israel Deaconess Medical Center, Boston, MA |
| Diana Passaro, PhD | The Francis Crick Institute, London, England |
| Chun Yew Fong, MD | Peter MacCallum Cancer Centre, Victoria, Australia |
| Alexander Höllein, MD | Technical University of Munich, Germany |
| Raphael Itzykson, MD, PhD | Hôpital Saint-Louis, Université Paris Diderot, France |
| Robert Kridel, MD | BC Cancer Agency, Vancouver, British Columbia, Canada |
| Kate Markey, MBBS, PhD | The Royal Brisbane and Women’s Hospital, Brisbane, Queensland, Australia |
| Mark Murakami, MD | Dana-Farber Cancer Institute, Boston, MA |
| Jyoti Nangalia, MBBChir | University of Cambridge, England |
| Elodie Pronier, PhD | Memorial Sloan Kettering Cancer Center, New York, NY |
| Suthesh Sivapalaratnam, MD | University of Cambridge, England |
| Elliot Stieglitz, MD | The University of California – San Francisco, CA |
| Elisa Ten Hacken, PhD | The University of Texas MD Anderson Cancer Center, Houston, TX |
| Iris Uras, PhD | Institute of Pharmacology and Toxicology, University of Veterinary Medicine, Vienna |
| Mireya Paulina Velasquez, MD | Baylor College of Medicine, Houston, TX |
| Janghee Woo, MD, PhD | University of Washington/Fred Hutchinson Cancer Research Center, Seattle, WA |
| Bas Wouters, MD, PhD | Erasmus Medical Center, Rotterdam, Netherlands |
About the American Society of Hematology:
The American Society of Hematology (ASH) (www.hematology.org) is the world’s largest professional society of hematologists dedicated to furthering the understanding, diagnosis, treatment, and prevention of disorders affecting the blood. For more than 50 years, the Society has led the development of hematology as a discipline by promoting research, patient care, education, training, and advocacy in hematology. The official journal of ASH is Blood (www.bloodjournal.org), the most cited peer-reviewed publication in the field, which is available weekly in print and online.
CONTACT:
Sara Khalaf, American Society of Hematology
[email protected]; 202-552-4925
Help ASH Build an Inclusive Hematology Community!
ASH is committed to building and nurturing a global hematology community and workforce inclusive of diverse perspectives, talents, and experiences as it works toward one collective goal: helping hematologists conquer blood diseases worldwide.
How Can You Help?
Visit your My Account page, make needed updates to your demographic details, and select your preferred level of ASH access to your information; aggregated or individually identifiable, or choose not to provide or share your information. By sharing information about who you are, you will help ASH have a better appreciation of the diverse needs and talents present in the field, and help to build a more inclusive, collaborative hematology community. It will take only a few moments to complete!
Update Access to Demographic Information Learn About Our Mission